These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31061688)

  • 1. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study.
    Santus P; Ferrando M; Baiardini I; Radovanovic D; Fattori A; Braido F
    World Allergy Organ J; 2019; 12(4):100030. PubMed ID: 31061688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
    Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
    Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.
    Sylwestrzak G; Liu J; Stephenson JJ; Ruggieri AP; DeVries A
    Am Health Drug Benefits; 2014 Apr; 7(2):71-81. PubMed ID: 24991392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence and patient preference for subcutaneous
    Gold R; Schmidt S; Deisenhammer F; Motte J; Richter N; Taipale K; Salmen HC; Bohland C; Schirduan K
    Ther Adv Neurol Disord; 2024; 17():17562864241241382. PubMed ID: 38616781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.
    van Deen WK; Khalil C; Bonthala NN; Gale R; Patel DB; Warui E; Melmed GY; Spiegel BMR
    Dig Dis; 2023; 41(3):412-421. PubMed ID: 36476714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Perspectives on Intravenous Biologics for Rheumatologic Disease.
    Grisanti L; Kwiatkowski A; Dyrda P; Field E; Grisanti J; Hatem J; Dehoratius RJ; Gaylis N
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1234-1242. PubMed ID: 30221490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE.
    Bell CF; Lau M; Lee M; Poulos C
    Clin Rheumatol; 2021 Feb; 40(2):581-590. PubMed ID: 32623647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.
    Overton PM; Shalet N; Somers F; Allen JA
    Patient Prefer Adherence; 2021; 15():811-834. PubMed ID: 33907384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer.
    Skalicky A; Bennett B; Raimbourg J; Lonardi S; Correll J; Lugowska I; Dixon M; Sargalo N; Martin ML
    Front Pharmacol; 2024; 15():1310546. PubMed ID: 38601466
    [No Abstract]   [Full Text] [Related]  

  • 10. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do patients with inflammatory bowel disease want their biological therapy administered?
    Allen PB; Lindsay H; Tham TC
    BMC Gastroenterol; 2010 Jan; 10():1. PubMed ID: 20064220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.
    Matucci A; Vultaggio A; Danesi R
    Respir Res; 2018 Aug; 19(1):154. PubMed ID: 30115042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs.
    Epstein RS
    Clinicoecon Outcomes Res; 2021; 13():801-807. PubMed ID: 34531668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study.
    De Mits S; Lenaerts J; Vander Cruyssen B; Mielants H; Westhovens R; Durez P; Elewaut D;
    PLoS One; 2016; 11(11):e0166607. PubMed ID: 27893771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis.
    Bril V; Lampe J; Cooper N; Kiessling P; Gardulf A
    J Comp Eff Res; 2024 Sep; 13(9):e230171. PubMed ID: 39115099
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study.
    Yang M; Chao J; Fillbrunn M; Mallya UG; Wang MJ; Franke L; Cohn L; Kamat S
    Patient Prefer Adherence; 2022; 16():2649-2661. PubMed ID: 36176349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
    Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri
    Wiendl H; Foley J; Defer G; Zhovtis Ryerson L; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Domingo-Horne R; Toukam M; Nunn A; Maghzi AH; Kuhelj R; Lasky T
    Neurol Ther; 2024 Oct; 13(5):1385-1401. PubMed ID: 39046635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
    Stoner KL; Harder H; Fallowfield LJ; Jenkins VA
    Patient; 2014 Jul; ():. PubMed ID: 25015302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.